TSCAN THERAPEUTICS INC. - COMMON STOCK

2.1700

21-February-25 15:45:00

15 minutes delayed

Stocks

-0.0200

-0.91%

Today's range

2.1500 - 2.3300

ISIN

N/A

Source

NASDAQ

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

05 Oct 2021 06:00:01 By Nasdaq GlobeNewswire
TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

28 Sep 2021 06:00:00 By Nasdaq GlobeNewswire
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

09 Sep 2021 15:05:00 By Nasdaq GlobeNewswire
TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

02 Sep 2021 06:00:01 By Nasdaq GlobeNewswire
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

19 Aug 2021 06:00:01 By Nasdaq GlobeNewswire
TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

21 Jul 2021 06:00:01 By Nasdaq GlobeNewswire
TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

15 Jul 2021 17:59:22 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.